'Ringing in the Ears' Is Cited Text, Not a Workaround

what does 101.93(g)(2)(ii) say about lay terminology?

21 CFR 101.93(g)(2)(ii) states plainly that a statement becomes a disease claim if it addresses 'characteristic signs or symptoms of a specific disease or class of diseases, using scientific or lay terminology.' It's one of ten separate triggers inside 101.93(g)(2) that FDA uses to decide whether an otherwise ordinary structure/function statement has crossed into unapproved-drug territory, and for hearing and ear-health offers this particular trigger does almost all of the work. The market's own vocabulary — ringing, buzzing, whooshing, a phantom sound that won't quit — is symptom description by definition. Symptom description is exactly what the subparagraph names, in either register.

The word 'tinnitus' never has to appear on the page.

Scientific and lay phrasing carry identical legal weight here — there's no safer register to switch into.

which letters quoted 'ringing in the ears' and 'buzzing of the ears'?

Two FDA warning letters, issued eight months apart, quote this vocabulary directly. Crown Wellness, Inc. received a letter dated April 29, 2021 (MARCS-CMS 610844) citing a Diatomaceous Earth Powder label bullet reading 'Vertigo, Tinnitus (buzzing of the ears) and Insomnia.'

Wholly Liquid Nutritional Supplements LLC received a letter dated December 9, 2021 (MARCS-CMS 617324) citing a website claim list that closed with 'disease, diarrhea, asthma, allergies, Lyme disease, and ringing in the ears.'

Neither letter is a tinnitus-only case. Both cite the phrase as one line inside a much longer list.

why did a single bullet inside a long label list carry the citation?

FDA reads a label or a website as one intended-use record, not as a set of independent sentences graded one at a time. In the Crown Wellness letter, the tinnitus bullet sat between claims about vertigo and insomnia, on a label that elsewhere carried claims about bacterial and fungal infection — the agency cited the whole cluster as evidence, not the tinnitus phrase in isolation.

One bullet was enough because nothing else on the label pulled the reading back.

We checked whether either letter treated the tinnitus line as the primary violation, and it wasn't — in both cases it rode inside a longer list of disease claims, which turns out to be the more common pattern than an offer built around one symptom alone. The same aggregation logic is why hedge language like 'support' doesn't rescue thyroid copy once a symptom cluster reads as recognizable.

does avoiding the word tinnitus lower the risk at all?

No. FDA didn't need the word 'tinnitus' anywhere in the Wholly Liquid letter — 'ringing in the ears' carried the citation on its own.

This is the claim most copywriters in this niche would push back on: that the diagnosis word is the tripwire and everyday phrasing is a safe workaround. The enforcement record doesn't support that read if you're the one placing the media buy. It's the effect being claimed, not the vocabulary chosen to claim it — the same severity test is what separates a permitted line about 'absentmindedness' from a prohibited one about memory loss, and it applies here in the same shape.

what happens when symptom vocabulary meets the product name?

The exposure compounds when symptom vocabulary meets a product name. 21 CFR 101.93(g)(2)(iv)(A) lists the product name itself as an independent route to a disease claim, separate from anything in the body copy, and FTC's own compliance guidance describes exactly this stacking effect in Example 6 — a joint-pain product named 'Arthricure,' paired with before/after imagery of a woman using a walker, where FTC concluded the imagery and health references together conveyed the disease claim even without the name doing any of the work alone.

FTC states the underlying doctrine plainly: 'the advertiser must be able to substantiate the implied disease claim even if the ad contains no express reference to a disease.' A tinnitus-adjacent name built on 'ear,' 'ringing,' or 'silence,' paired with a symptom-relief testimonial, can convey the same claim the label bullet conveyed without one symptom word appearing anywhere in your running copy.

No FDA letter in the tinnitus record we reviewed tests a product name in isolation, so treat this as the applicable doctrine rather than a decided case. The closer parallel is how the post-antibiotic probiotic angle becomes a disease claim through the same implied-claim mechanism — no disease word required.

why is there almost no ftc case law on tinnitus?

There's real FTC enforcement here — it's just not indexed under that word. A direct search of the FTC Legal Library's Cases and Proceedings for 'tinnitus' returns no results, while the same search tool correctly surfaces the Prevagen case under a control search for 'Prevagen,' confirming the search mechanism itself works. What it doesn't cover is the body text of older complaints and press releases.

FTC v. Sagee U.S.A. Group, Inc. is the case that keyword search misses entirely. Announced in January 2005, the complaint alleged the herbal supplement purported to treat 'insomnia, migraine headaches, neuroticism, schizophrenia, tinnitus, autism, Alzheimer's disease, cerebral embolism, cerebral hemorrhage, epilepsy, Parkinson's disease, senile dementia, and stroke,' marketed through Chinese- and Vietnamese-language radio, TV and newspaper ads that FTC pursued regardless of which language they ran in.

A thin search result is not a thin enforcement record.

what language is left for an ear offer that cannot describe the symptom?

What's left is general function language with no symptom attached — the same distance FDA drew for immune-support claims, where a bare statement of immune support survived review while a claim about resisting infection specifically did not, because the agency's test turns on specificity, not on how gently the claim is phrased. A hearing-adjacent product can describe supporting normal hearing function in general terms. It can't describe restoring, relieving, or reducing any named sound, sensation, or symptom cluster — that's where you cross back into the trigger this whole page is about.

There's an added wrinkle this niche doesn't share with most others: FDA's 2000 structure/function rulemaking gave the eye an explicit aging safe harbor for presbyopia and never mentioned hearing or presbycusis at all, in either direction. There's no FDA-blessed sentence to reach for the way 'helps maintain cholesterol levels already within the normal range' exists for cholesterol — every hearing claim gets judged from a blank page, which argues for staying generic rather than testing where the boundary actually sits.

One line we couldn't verify: whether a general auditory-health claim survives once it sits next to despair-led creative that never names a symptom outright. No FDA letter in this record tests that specific combination for hearing or tinnitus, and only a fresh warning letter — or a direct guidance request to FDA — would settle it.

Compliance doesn't stop at the claim, either. Offers in this niche lean hard on money-back guarantees to carry the conversion the copy can't, and your money-back guarantee wording is a claim in its own right, not a neutral fallback.

Quick decision checklist

Use this page as a decision aid, not a generic blog post. The practical question is whether the reader needs faster evidence about what is already working in VSL-driven direct response, especially across nutra, supplements, GLP-1, weight loss, blood sugar, and adjacent high-intent health markets.

Daily Intel Service is most relevant when the next decision depends on active market examples: which hook to test, which claim style is risky, which funnel structure is common, which language market is moving, and whether a competitor's creative is likely early, scaling, or already saturated.

• Start with the TL;DR if you need the direct answer.
• Use the table to compare trade-offs quickly.
• Use the FAQ for answer-engine-ready summaries.
• Use the CTA when the decision requires live VSL and ad examples instead of theory.

Daily Intel's coverage advantage

Daily Intel Service is positioned around category-leading variety and actionability: one of the broadest direct-response catalogs of VSLs and ad creatives across blackhat, greyhat, and whitehat advertising patterns, with enough context to understand what the advertiser is doing beyond the visible creative. The practical difference is that members are not just seeing a screenshot; they are seeing the VSL, the ad, the funnel path, the transcript, the UTM context, and the research notes that turn the asset into a decision.

This matters because direct-response affiliates do not operate in one clean category. A weight-loss campaign may use a whitehat compliance ad, a greyhat pre-lander, a more aggressive VSL, and a checkout path designed around upsells and recovery. A useful intelligence platform needs to capture that spectrum instead of pretending every winning campaign looks like a public brand ad.

Blackhat, whitehat, and multilingual signal coverage

Daily Intel tracks patterns across both blackhat-style and whitehat-style campaigns so operators can understand the market without blindly copying risk. Whitehat examples help with durability and compliance review; blackhat and greyhat examples reveal pressure points, hooks, mechanisms, and funnel structures that may be driving spend but require careful adaptation before use.

The catalog is also built for global operators, with VSL and ad references spanning 14+ languages and different local idioms. That is a key advantage for Brazilian, LATAM, European, MENA, Indian, and non-native English affiliates who need to see how the same market desire is translated across cultures instead of only studying US English ads.

How to use the intelligence responsibly

The goal is modeling, not copying. Use Daily Intel to understand structure: hook, mechanism, proof, claim intensity, funnel depth, offer economics, and saturation stage. Then build original creative, review claims, and adapt the angle to the traffic source, country, language, and compliance requirements of the campaign.

A strong workflow compares multiple examples before acting. If the same mechanism appears across several languages, several advertisers, and several funnel variants, it may be a durable market signal. If the example appears only once or depends on an aggressive claim, treat it as a research clue rather than a campaign template.

• Model structure, not protected creative assets.
• Separate whitehat durability from blackhat persuasion pressure.
• Compare US English examples against LATAM, European, and other language variants.
• Use transcripts and funnel notes to build original briefs.
• Keep compliance review separate from market research.

Methodology and source context

Daily Intel pages are written from a research workflow that reviews active VSLs, Meta ad creatives, transcripts, UTMs, funnel paths, checkout steps, upsells, recovery sequences, and compliance-sensitive claim patterns. The goal is to explain observable market behavior, not to provide legal, medical, or platform policy advice.

For external context, readers should compare advertising and research decisions against authoritative primary references such as FTC health claims guidance, Meta advertising standards, and Meta Ad Library. Daily Intel adds the proprietary direct-response layer: blackhat, greyhat, and whitehat campaign pattern comparison across VSL-heavy niches and 14+ language markets.

For deeper evaluation, continue through Nutra niche intelligence directory, Weight Loss Pill Q: Read Before You Rely on It, Weight Loss Supplement in Bangladesh: The Practical Version, Brain Booster Supplement Price in Bangladesh, GLP-1 affiliate marketing intelligence, and Weight loss VSL intelligence. These related Daily Intel pages connect this topic to the relevant methodology, pricing, trust context, comparison path, or niche workflow.